News

Quotient featured in Drug Development & Delivery's Solubility Special Feature Report

Quotient's Vice President of Drug Development Sciences, Dr Sarah Stevens, discusses our integrated approach to accelerating the development of poorly soluble compounds in Drug Development & Delivery's Special Feature article entitled: "Improving Bioavailability & Solubility: Each Molecule Is Unique"

Quotient Sciences: Integrated Approach Accelerates Drug Development

Solving bioavailability and solubil­ity challenges to support successful drug delivery is an ever-enduring challenge (and opportunity) for phar­maceutical formulation scientists. Along with well-established ap­proaches to improving each, there are many emerging platform technolo­gies, providing options in the toolbox. In many ways, though, availability of such formulation and process technol­ogy approaches does not present the primary barrier to improving universal solubility and bioavailability chal­lenges. Instead, a key challenge is the continued lack of predictive, clinically relevant models to guide formulation selection early enough in the develop­ment process – such that money and time are not unnecessarily expended, and avoidable risks not taken.

“With many examples of mislead­ing nonclinical and in vitro predictabil­ity out there, robust predictive models would afford the ability to understand and adapt for successful clinical out­comes from the outset,” says Dr. Sarah Stevens, Vice President of Drug Development Sciences at Quotient Sciences. “Quotient Sciences embod­ies science-led decision making, therefore not relying simply on poten­tially unreliable predictive models. A combination of unique development approaches provides the most expedi­tious means to improve potential bioavailability and solubility chal­lenges.”

Quotient, she says, deploys technologies such as particle size reduction, lipid-based formulation mechanisms, HME, SDD, etc., but more pertinently, drives early formula­tion selection by cutting through in­dustry silos and integrating across a range of capabilities to accelerate the drug development process. One ex­ample is Quotient’s Translational Pharmaceutics® platform, which inte­grates drug product manufacturing and clinical testing and ensures a con­tinuum among lead compound selec­tion, formulation development, and clinical assessments. “This reduces formulation development timelines and money, and mitigates risk in the development pathway by utilizing real-time clinical data to improve bioavailability and solubility,” says Dr. Stevens.

This integrated approach requires finely tuned project management and processes to ensure the most expedi­tious path to evaluate new molecules and formulations in the clinic. Prior to any clinical assessment, Quotient de­ploys a number of approaches based around the Developability Classifica­tion System (DCS) to deeply under­stand molecule properties – physico­chemical characterization, the use of biorelevant methods and physiologi­cally-based modelling/simulation to best position the formulation strategy for success. Quotient uses real-time product manufacturing and clinical testing to make, dose, and test new dosage forms within a 14-day cycle time, using arising clinical PK data to adjust formulation compositions.

As an example, she explains how Quotient rapidly screened a range of formulation types, including a mi­cronized API, spray-dried dispersions, and a lipid-based formulation using both biorelevant media and the inte­grated clinical manufacturing and testing platform.

“Nonclinical data was unable to provide clarity on which formulation strategy would be optimal to address PK issues seen with a simple first-in-human suspension system,” says Dr. Stevens. “Our ability to make decisions based on human PK data al­lowed identification of a powder-in-capsule formulation containing micronized drug, which demonstrated improved exposure, linear PK, and a reduced food effect, saving time and money for our client. This example supports my assertion that the lack of predictive, non-clinical or biorelevant models is the real barrier to success in the development of bioavailability/sol­ubility enhancing formulations.”

To access the full article click: https://drug-dev.com/special-feature-improving-bioavailability-solubility-each-molecule-is-unique/

We use cookies to help us to improve our site and enables us to the best possible service and customer experience. By clicking accept you are agreeing to let us share your data with select third parties for analytics and marketing purposes.